A phase 1 mechanism of action study of intratumoral or intravenous administration of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus in colon cancer patients undergoing resection of primary tumor

Autor:	Juan M. Bozada, Emiliano Calvo, Cristina Santos, Valentina Boni, Antonio Cubillo, Christopher Ellis, Monica Jurado, Susana Prados, Simon Alvis, Fernando de la Portilla, C. Blanc, John Beadle, Kerry D. Fisher, M. Gil-Martin, Amparo Sanchez-Gastaldo, Hipolito Duran, Ramon Salazar, Xavier Sanjuan, Rocio Garcia-Carbonero
Rok vydání:	2014
Předmět:	Cancer Research Pathology medicine.medical_specialty Enadenotucirev Colorectal cancer business.industry viruses medicine.disease Primary tumor Clinical success Group B Resection Oncolytic virus Oncology Mechanism of action Cancer research medicine medicine.symptom business
Zdroj:	Journal of Clinical Oncology. 32:TPS3112-TPS3112
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2014.32.15_suppl.tps3112
Popis:	TPS3112 Background: To date convincing clinical success with oncolytic viruses tends to be associated with intra-tumoral (IT) administration and evidence for successful systemic delivery of viruses...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::481ee1fb5c1a2e5fca36c8f32458a4db https://doi.org/10.1200/jco.2014.32.15_suppl.tps3112 Zobrazit plný text záznamu